PDL BioPharma, Inc.
PDL BIOPHARMA, INC. (Form: 8-K, Received: 01/09/2017 06:20:32)


 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 9, 2017

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)


Delaware
 
94-3023969
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)


932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 








Item 7.01 Other Events.
 
Beginning on January 9, 2017, PDL BioPharma, Inc. (the Company) will participate in conferences with investors and analysts during the 35th Annual JP Morgan Healthcare Conference in San Francisco, California. A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s 2015 Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 23, 2016, and updated in subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
 
Description
 
 
 
99.1
 
Presentation






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)
 
 
 
By:
 
/s/ Peter S. Garcia
 
 
Peter S. Garcia
 
 
Vice President and Chief Financial Officer




Dated: January 9, 2017






Exhibit Index


Exhibit No.
 
Description
99.1
 
Presentation







Exhibit 99.1
SLIDE01.JPG





SLIDE02.JPG





SLIDE03.JPG





SLIDE04.JPG





SLIDE05.JPG





SLIDE06.JPG





SLIDE07.JPG





SLIDE08.JPG





SLIDE9A25.JPG





SLIDG98.JPG





SLIDG99.JPG





SLIDH01.JPG





SLIDH02.JPG





SLIDH03.JPG





SLIDH04.JPG





SLIDH05.JPG





SLIDH06.JPG





SLIDH07.JPG





SLIDH08.JPG





SLIDH09.JPG





SLIDH10.JPG





SLIDH11.JPG





SLIDH12.JPG





SLIDH13.JPG





SLIDH14.JPG





SLIDH15.JPG





SLIDH16.JPG





SLIDH17.JPG





SLIDH18.JPG





SLIDH19.JPG





SLIDH20.JPG





SLIDH21.JPG





SLIDH22.JPG





SLIDH23.JPG





SLIDH24.JPG





SLIDH25.JPG





SLIDH26.JPG





SLIDH27.JPG





SLIDH28.JPG





SLIDH29.JPG





SLIDH30.JPG





SLIDH31.JPG





SLIDH32.JPG





SLIDH33.JPG